- Longevity Health Holdings (XAGE, Financial) to merge with THPlasma in a $59 million all-stock transaction, plus $20 million in earnouts.
- THPlasma's revenue projected to grow from $10 million in FY2025 to $32 million in FY2026.
- The merger will see THPlasma's George Chi take on the role of Co-Chairman and CEO of the combined entity.
Longevity Health Holdings, Inc. (NASDAQ:XAGE) has announced a definitive merger agreement with THPlasma, a profitable plasma collection company, in an all-stock transaction valued at $59 million, plus $20 million contingent on performance earnouts. This strategic move follows Longevity's recent acquisitions, including Carmell Therapeutics and Elevai Skincare, and marks a pivot towards expanding in the plasma industry.
THPlasma is forecasting substantial growth, with revenues expected to jump from $10 million in FY2025 to $32 million in FY2026, representing a significant 220% year-over-year increase. The firm, which currently operates two plasma collection centers, plans to expand to five centers by FY2025, bolstered by guaranteed sales agreements worth $100 million annually.
Upon the merger's completion, anticipated in the fourth quarter of 2025 subject to stockholder approvals, the combined company will continue to trade as XAGE on NASDAQ. THPlasma's George Chi will assume the role of Co-Chairman and CEO, while Longevity's Rajiv Shukla will serve as Executive Chairman. This alignment aims to bolster the company's market position and address global plasma supply challenges, with the U.S. supplying 60% of the world's plasma.
Simultaneously, Longevity has terminated its previously planned merger with 20/20 BioLabs. The merger with THPlasma is expected to provide the combined entity access to public markets and future M&A opportunities, while driving value through strategic growth initiatives.
